Bone-Targeting PTH Receptor Agonist Conjugate for Fracture Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical treatments for bone fractures lack site-specific anabolic drugs, with approved drugs like BMP-2 and BMP-7 having limited use and primarily applied locally, failing to address the broader need for systemic treatment of osteoporotic fractures, which are increasingly prevalent due to an aging population.
Innovation Solution
A compound comprising a formula X—Y—Z, where X is an agent modulating parathyroid hormone receptors, Y is a linker, and Z is a negatively charged oligopeptide that binds to hydroxyapatite, providing a systemic treatment that targets bone fractures effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If locally administered drugs like BMP-2 and BMP-7 are used to treat bone fractures, then bone healing at the fracture site is promoted, but the treatment is limited to open fractures and carries risks of infection and requires surgical intervention
Solution Approach 1:
The patent uses a bone-targeting molecule as an intermediary carrier that delivers the anabolic drug specifically to the fracture site. This mediator enables systemic administration while achieving localized effect, thus avoiding the infection risks of local injection and surgery while maintaining bone healing effectiveness
Solution Approach 2:
The invention exploits the body's natural bone healing process and the inherent targeting capability of bone-seeking molecules. The system uses the body's own physiological mechanisms to guide drug delivery to the fracture site, eliminating the need for surgical intervention and reducing external harm while maintaining therapeutic effectiveness
2Adaptability or versatility
If systemic anabolic drugs are administered to treat osteoporotic fractures, then broader application is possible, but currently no approved drugs exist for systemic use in fractures
Solution Approach 1:
The patent creates a universal treatment platform that can be applied to various types of bone fractures including osteoporotic fractures, traumatic fractures, and other bone malades. The bone-targeting molecule anabolic drug conjugate serves multiple functions: systemic administration, fracture site targeting, and anabolic stimulation, enabling broad clinical applicability
Solution Approach 2:
The invention changes the delivery parameter from local to systemic administration while maintaining effective drug concentration at the target site through the bone-targeting molecule. This parameter change enables treatment of previously inaccessible fracture types and expands clinical utility
3Measurement precision
If locally administered drugs are used for bone fractures, then targeted delivery is achieved, but the treatment is restricted to open fractures and does not address closed or osteoporotic fractures
Solution Approach 1:
The bone-targeting molecule serves as an intermediary that enables the anabolic drug to reach the fracture site specifically through systemic circulation. This mediator maintains high targeting precision while allowing the drug to access various fracture types including closed and osteoporotic fractures that are inaccessible to local administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound enhances bone density and healing at fracture sites, offering a more effective and targeted approach compared to traditional treatments, reducing the risk of systemic side effects and infection associated with local applications.
Implementation Method 1
Z is at least one negatively charged oligopeptide or an equivalent thereof that binds to hydroxyapatite and/or raw bone
Data Source
AI summary
Disclosed herein includes a drug delivery system comprising at least one peptide and a targeting ligand for bone fracture and/or for bone healing. Some embodiments include a peptide delivery system comprising at least an acidic, basic, hydrophilic, hydrophobic or neutral peptide linked to an acidic peptide or nonpeptidic polyanion for use in targeting the aforementioned attached peptide to a bone fracture surface. In some embodiments, a conjugated peptide expresses an anabolic function that acts through PTH receptor 1, and various formats of targeting ligands guide the drug to raw hydroxyapatite. This system offsets some side effects caused by free anabolic drug, such as high blood calcium concentration